Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release


Media Contacts:


Suzanne Frost


+1 416-317-0304


Brian Kenney +1 215-620-0111

...

Related Keywords

United Kingdom ,Madrid ,Spain ,James Wf Catto ,Indianj Urol ,Clin Urol ,Obrian Kenney ,Kiran Patel ,Jnjinnovmedand Janssen ,Exchange Commission ,Drug Administration ,Johnson ,Clinical Development ,Companies Of Johnson ,European Society For Medical Oncology ,Department Of Oncology ,European Society For Medical Oncology Congress ,None Of Janssen Research Development ,Janssen Research Development ,Astex Pharmaceuticals ,Us Food Drug Administration ,University Of Sheffield ,Janssen Biotech Inc ,Janssen Pharmaceutical Companies Of Johnson ,News Release ,Show Improved Rates ,Recurrence Free Survival ,High Risknon Muscle Invasive Bladder Cancer ,Janssen Pharmaceutical Companies ,Bacillus Calmette Gu ,Proffered Paper ,European Society ,Medical Oncology ,Hazard Ratio ,Confidence Interval ,Vice President ,Solid Tumors ,Janssen Research ,Supplemental New Drug Application ,European Medicines Agency ,Janssen Pharmaceutica ,Soft Tissue Mineralization ,Specific Populations ,Prescribing Informationfor ,Pharmaceutical Companies ,Pulmonary Hypertension ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,With High Risknon Muscle Invasive Bladder Cancer ,Who Received Prior Bacillus Calmette Gu ,Participants With Advanced Solid Tumors ,Fibroblast Growth Factor Receptor ,Accessed May ,Unresponsivenon Muscle Invasive Bladder Cancer ,Current Treatment Landscape ,Novel Emerging Molecular ,Intj Mol ,Markets ,